Congenital prothrombin deficiency: an update.

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Prothrombin (factor II [FII]) deficiency is a rare inherited coagulation disorder with a prevalence of 1 in 2,000,000.
• Two phenotypes exist: true hypoprothrombinemia (low antigen levels) and dysprothrombinemia (functional protein defect).
• Mutations in the catalytic domain of thrombin can impair antithrombin interaction, potentially leading to thromboembolic events.

Purpose of the Study:

• To review the genetic basis and clinical manifestations of prothrombin deficiency.
• To discuss the different types of mutations identified in prothrombin deficiency.
• To present and discuss recent therapeutic developments for congenital prothrombin deficiency.

Main Methods:

• Literature review of studies on prothrombin deficiency.
• Analysis of genetic mutations and their impact on protein function.
• Discussion of current and emerging therapeutic strategies.

Main Results:

• Thirty-nine distinct mutations in the prothrombin gene have been identified, affecting various functional domains.
• Mutations are predominantly missense, but nonsense mutations and deletions also occur.
• Recent therapeutic advancements offer new hope for managing congenital prothrombin deficiency.

Conclusions:

• Prothrombin deficiency presents with diverse phenotypes due to various genetic mutations.
• Understanding genotype-phenotype correlations is crucial for patient management.
• Ongoing research and therapeutic innovations are improving treatment outcomes for prothrombin deficiency.